Brii Biosciences Ltd
02137
Company Profile
Business description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Contact
No. 1 North Yongtaizhuang Road
3rd Floor, Building 7, Zhongguancun Dongsheng
International Science Park
Haidian District
Beijing100192
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
95
Stocks News & Analysis
stocks
2 undervalued ASX shares report
These two ASX shares are trading at a discount to our fair value.
stocks
Turmoil at WiseTech
Board members step down over differences on the role of former CEO Richard White.
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,494.50 | 65.60 | -0.77% |
| CAC 40 | 8,090.99 | 63.52 | -0.78% |
| DAX 40 | 22,425.93 | 138.37 | 0.62% |
| Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
| FTSE 100 | 8,658.98 | 0.39 | -0.00% |
| HKSE | 22,998.69 | 342.92 | -1.47% |
| NASDAQ | 19,286.93 | 237.08 | -1.21% |
| Nikkei 225 | 38,345.99 | 430.95 | -1.11% |
| NZX 50 Index | 12,355.74 | 175.98 | -1.40% |
| S&P 500 | 5,983.25 | 29.88 | -0.50% |
| S&P/ASX 200 | 8,247.00 | 61.20 | -0.74% |
| SSE Composite Index | 3,359.27 | 13.76 | -0.41% |